explore -WSS

explore

author：hotspot 2025-10-01 23:02:25 - browse：26591

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Supreme Court strikes down use of affirmative action
Next article： Asbestos ban is immediate, but health effects will linger for decades

WSS

Why patients can’t get everything they want on drug pricing

Erich Jarvis studies song birds to learn about human stuttering

Dems pitch expanding Medicare power to negotiate drug prices

How doctors’ personal politics affect patients

Diabetes management: Digital health tools fall short, study says

What causes rare myocarditis in young men after Covid vaccines?

hotspot

explore

entertainment

Medical leaders decry Supreme Court decision on affirmative action

New lawsuit accuses health insurer Cigna of denying claims in bulk

Peter Hotez and the public health issue of online harassment

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

United colonoscopy coverage change 'may cost lives,' doctors say

In the gardens at Boston Children's Hospital, families find sanctuary

In age of alternative facts, a scholarly course on calling out crap

Medicare Advantage insurers pressure Biden for bigger payments

Moonlake's readout produced a cash windfall. Risks remain

The battle over 'scope creep' and who gets to be called 'doctor'

leisure time

Diabetes management: Digital health tools fall short, study says

6 surprising facts about sugar

Asbestos ban is immediate, but health effects will linger for decades

Steward Health Care expansion into Malta flopped

STAT Report: Patient voices and perspectives

Testing GLP

entertainment

focus

focus

explore